Key result
Calpain inhibition attenuates cardiac hypertrophy in preclinical models, emerging as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Cardiac hypertrophy develops most commonly in response to hypertension and is an independent risk factor for the development of heart failure. The mechanisms by which cardiac hypertrophy may be reversed to reduce this risk have not been fully determined to the point where mechanism-specific therapies have been developed. Recently, proteases in the calpain family have been implicated in the regulation of the development of cardiac hypertrophy in preclinical animal models. In this review, we summarize the molecular mechanisms by which calpain inhibition has been shown to modulate the development of cardiac (specifically ventricular) hypertrophy. The context within which calpain inhibition might be developed for therapeutic intervention of cardiac hypertrophy is then discussed.
No takes yet. Share an insight, caveat, or question.
Patterson et al. (2011) conducted a review in Cardiac hypertrophy. Calpain inhibition was evaluated. Calpain inhibition has been shown to modulate the development of cardiac hypertrophy in preclinical animal models, presenting a potential mechanism-specific target for therapeutic intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: